1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi

Dual Action Stands Out From Lilly’s Kisunla

 
• By Mandy Jackson

Leqembi for early Alzheimer’s disease now has an anti-amyloid competitor in the US with limited-term dosing, but new data at AAIC support chronic dosing of Eisai’s Biogen-partnered drug.

Caregiver cheers up senior lady patient touching hand while sits in armchairs in light room
Maintenance and subcutaneous dosing could reduce the burden of chronic Leqembi treatment • Source: Shutterstock

New long-term data on Eisai Co., Ltd./Biogen, Inc.’s early Alzheimer’s disease medicine Leqembi (lecanemab) presented at the Alzheimer’s Association International Conference (AAIC) indicate that chronic treatment has a better effect than short-term treatment, possibly negating what was thought to be a potential advantage for Eli Lilly and Company’s competing anti-amyloid antibody Kisunla (donanemab).

Key Takeaways

  • Eisai and Biogen have a first-to-market advantage in early Alzheimer’s disease with Leqembi, but a second anti-amyloid antibody has reached the market from Lilly with potential dosing advantages.

Leqembi has been on the market in the US since receiving accelerated approval in January 2023, giving it a year...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.